High-carbohydrate–low-glycaemic index dietary advice improves glucose disposition index in subjects with impaired glucose tolerance

Thomas M. S. Wolever* and Christine Mehling
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada M5S 3E2 and Division of Endocrinology and Metabolism, St. Michael’s Hospital, Toronto, Ontario, Canada
(Received 5 June 2001 – Revised 26 November 2001 – Accepted 20 January 2002)

Controversy exists about the optimal amount and source of dietary carbohydrate for managing insulin resistance. Therefore, we compared the effects on insulin sensitivity (SI), pancreatic responsivity (AIRglu) and glucose disposition index (DI = SI × AIRglu) of dietary advice aimed at reducing the amount or altering the source of dietary carbohydrate in subjects with impaired glucose tolerance (IGT). Subjects were randomized to high-carbohydrate–high-glycaemic index (GI) (high-GI, n = 11), high-carbohydrate–low-GI (low-GI, n = 13), or low-carbohydrate–high-monounsaturated fat (MUFA, n = 11) dietary advice, with SI, AIRglu and DI measured using a frequently sampled, intravenous glucose tolerance test before and after 4 months treatment. Carbohydrate and fat intakes and diet GI, respectively, were: high-GI, 53 %, 28 %, 83; low-GI, 55 %, 25 %, 76; MUFA, 47 %, 35 %, 82. Weight changes on each diet differed significantly from each other: high-GI, +0.49 (SEM 0.29) kg; low-GI, +0.19 (SEM 0.40) kg; MUFA +0.27 (SEM 0.45) kg. Blood lipids did not change, but glycated haemoglobin increased significantly on MUFA, 0.02 (SEM 0.11) %, relative to low-GI, −0.19 (SEM 0.08) %, and high-GI, −0.13 (SEM 0.14) %. Diastolic blood pressure fell by 8 mmHg on low-GI relative to MUFA (P = 0.038). Although SI and AIRglu did not change significantly, DI, a measure of the ability of β-cells to overcome insulin resistance by increasing insulin secretion, increased on low-GI by +50 % (P = 0.02). After adjusting for baseline values, the increase in DI on low-GI, 0.07 (SEM 0.07), was significantly greater than those on MUFA, −0.09 (SEM 0.08) and high-GI, −0.03 (SEM 0.02) (P = 0.019). Thus, the long-term effects of altering the source of dietary carbohydrate differ from those of altering the amount. High-carbohydrate–low-GI dietary advice improved β-cell function in subjects with IGT, and may, therefore, be useful in the management of IGT.

Dietary carbohydrates: Insulin sensitivity: Insulin secretion: Clinical trial

Over the past 20–25 years, high-carbohydrate, low-fat diets have been recommended for the general public (US Department of Agriculture, 1990; Food and Agricultural Organization of the United Nations, 1998). This advice is challenged by recent data showing that, compared with diets high in monounsaturated fat, high-carbohydrate diets raise plasma glucose, insulin and triacylglycerol and reduce HDL-cholesterol (Garg et al. 1994; Jeppesen et al. 1997), factors associated with atherosclerosis (Stout, 1990) and CHD (Balkau et al. 1998; Gordon & Rifkind, 1989; Hokanson & Austin, 1996). Furthermore, a high-carbohydrate diet raised plasma insulin to the greatest extent in people with insulin resistance (Jeppesen et al. 1997), which itself is associated with increased risk of obesity, cardiovascular disease, diabetes, and hypertension (Reaven, 1995). Thus it has been suggested that, since high-carbohydrate diets exacerbate the metabolic abnormalities of insulin resistance, they are deleterious for treating insulin resistance (Reaven, 1997).

However, not only are there few data on the effect of high-carbohydrate v. high-monounsaturated fat diets in insulin-resistant, non-diabetic subjects, but also few studies comparing the effects of low- and high-carbohydrate diets have taken into account the source of dietary carbohydrate

Abbreviations: AIRglu, pancreatic responsivity; DI, glucose disposition index; FSIGTT, frequently sampled intravenous glucose tolerance test; FSD, fractional standard deviation; GI, glycaemic index; HbA1c, glycated haemoglobin; high-GI, high-carbohydrate–high glycaemic index diet; IGT, impaired glucose tolerance; low-GI, high-carbohydrate–low-glycaemic index diet; MUFA, low-carbohydrate–high monounsaturated fat diet; NEFA, non-esterified fatty acids; SI, insulin sensitivity.

* Corresponding author: Dr Thomas M. S. Wolever, fax +1 416 978 5882, email thomas.wolever@utoronto.ca
Different carbohydrate foods are digested in vitro at different rates (Jenkins et al. 1982), which, in turn, are directly related to the blood glucose and insulin responses they elicit (Wolever et al. 1988). The glycaemic responses of foods are classified using the glycaemic index (GI) (Wolever et al. 1991). The incorporation of low-GI foods into mixed meals reduces glucose and insulin responses in normal (Chew et al. 1988) and diabetic subjects (Indar-Brown et al. 1992). Also, low-GI and high carbohydrate meals reduce postprandial non-esterified fatty acid (NEFA) concentrations (Wolever et al. 1995), which, in turn, may improve insulin secretion (Zhou & Grill, 1994; Carpentier et al. 1999) and insulin action (Boden et al. 1994). Since the pathogenesis of type 2 diabetes involves defects in insulin action and insulin secretion (Ferrannini, 1998; Gerich, 1998), consideration of both insulin secretion and insulin sensitivity is important for those at risk of type 2 diabetes.

Since there is controversy about the optimal source and amount of carbohydrate for the management of insulin resistance, we compared the effects of altering the source of dietary carbohydrate with those of altering the amount of carbohydrate on insulin secretion and insulin sensitivity in subjects with impaired glucose tolerance (IGT). Reducing diet GI and reducing carbohydrate intake can have similar acute effects on reducing postprandial glucose and insulin responses. However, we hypothesized that these dietary manoeuvres would have different effects on insulin sensitivity and secretion in subjects with IGT.

**Methods**

A total of 257 subjects with at least one risk factor for diabetes (obesity, family history of diabetes, previous gestational diabetes, previous high blood glucose or diabetes (obesity, family history of diabetes, previous gestational diabetes, previous high blood glucose or diabetes) were prescribed on an ad-libitum used as a basis for individualized dietary advice. Diets 7·0 mmol/l, would now be considered to have diabetes. (6·1–6·9 mmol/l) and one, with fasting plasma glucose of 7·8 mmol/l and plasma glucose 2 h after 75 g oral glucose 11·1 mmol/l (World Health Organization, 1980). Diagnostic criteria for diabetes changed after recruitment started (American Diabetes Association, 1980). The American Diabetes Association (ADA) recommended that diagnostic criteria for diabetes be based on oral glucose tolerance test (OGTT) (WHO, 1979). Glycated haemoglobin (HbA1c) was measured by Diamat HPLC (Bio-Rad Laboratories (Canada) Ltd., Mississauga, Ontario, Canada). Fasting insulin (I) was injected at time 0 min and further blood samples taken at 2, 3, 4, 6, 8, 10, 12, 14, 16 and 19 min. At 20 min, insulin (I) was injected and blood samples obtained at 22, 23, 24, 25, 27, 30, 40, 50, 60, 70, 80, 100, 120, 140, 160, 180, 200, 220 and 240 min. Plasma glucose and insulin results were analysed using the MINMOD computer program (Pacini & Bergman, 1986).

Fasting total cholesterol and triacylglycerol were measured using a Vitros Analyser 950 (Johnson & Johnson Clinical Diagnostics, Rochester, NY) with HDL-cholesterol measured after precipitation of other lipoproteins with dextran sulfate and magnesium chloride. LDL-cholesterol was calculated as total cholesterol – (HDL + triacylglycerols;2/2) (only for triacylglycerol <4·51 mmol/l). Glycated haemoglobin (HbA1c) was measured by Diamat HPLC (Bio-Rad Laboratories (Canada) Ltd., Mississauga, Ontario, Canada). Fasting insulin (I) was injected and blood samples obtained at 22, 23, 24, 25, 27, 30, 40, 50, 60, 70, 80, 100, 120, 140, 160, 180, 200, 220 and 240 min. Plasma glucose and insulin results were measured at baseline and 4 months using a commercial kit (NEFA C, ACS-ACOD Method; WAKO Chemicals USA, Richmond, VA).

Of forty-four eligible subjects, seven declined, and thirty-seven were randomized by coin toss, with stratification for age, gender and BMI, to receive one of the three test diets. Two high-GI and one MUFA subjects dropped out before the study ended. One subject participated in two arms of the study (MUFA and high-GI). For comparison with baseline data from IGT subjects, eight lean and seven obese normal controls underwent the FSIGTT.

The number of subjects studied was based on two considerations. The intra-individual variation of S̃₁ in healthy young subjects has been reported to have a CV of 14·4 % (Ferrari et al. 1991). Using this CV, with twelve subjects in each group, there would be 90 % power to detect a difference in S̃₁ of 20 % (StatMate version 1.01; Graph Pad software, San Diego, CA). Using a different method to measure insulin sensitivity, we found that acarbose
and obese control subjects differed significantly from each other. There was no significant difference in any parameter at baseline among the groups of IGT subjects randomized to the high-GI, low-GI or MUFA diets (Table 2, serum lipids and NEFA not shown).

Recorded energy intake during the study fell by about 690 kJ on low-GI, increased by about 880 kJ on MUFA and did not change on high-GI (diet × time interaction, \( P=0.03 \), Table 3). Subjects on MUFA recorded about 7 and 5 % less carbohydrate and about 8 and 11 % more total fat intake than those on low- and high-GI, respectively (\( P<0.05 \)). The differences in total fat were accounted for by differences in monounsaturated fat. Subjects on low-GI recorded about 13 g/d more dietary fibre and lower diet GI than those on the other two diets. Glycaemic load was significantly lower on MUFA than high-GI, with the value on low-GI being intermediate. The percentage of total energy contributed by various food groups before and during the dietary treatments is shown in Fig. 2. On high-GI, subjects increased their intake of high-GI starchy foods by 8 % of energy, with about a 4 % reduction in low-GI starchy foods and smaller reductions in fats, oils, nuts and mixed dishes. On the low-GI diet, there were small (<2 % energy) changes in intake of foods from several food groups; the main changes were an increased intake of low-GI starch (11 %) and low-GI soups (3 %) and a reduced intake of high-GI starch (8 %). On the MUFA diet, subjects increased intake of fats, oils and nuts by about 9 % of energy and reduced intake of dairy foods by 4 %, with smaller reductions in high-GI starch, meats, and fruits and vegetables.

Mean body weight changes were very small, but there was a significant main effect of diet (Fig. 3(a)). Body weight tended to decrease on high-GI and low-GI and to increase on MUFA. The mean fall in body weight over weeks 4–16 on high-GI, −0.49 (SEM 0.29) kg, was significantly greater than that on low-GI, −0.19 (SEM 0.40) kg, which, in turn, was significantly different from the small

### Results

Characteristics of IGT and control subjects are shown in Table 1. IGT and obese control subjects were of similar age and BMI, but were significantly older and more obese than lean controls. Generally, metabolic parameters were significantly impaired in IGT subjects relative to lean controls, with obese control values being intermediate. There was no difference between IGT and control subjects for serum lipids and NEFA. \( S_1 \) and \( \text{AIR}_{\text{glu}} \) were significantly lower in IGT subjects than lean controls, with values for obese controls being intermediate (Table 1, Fig. 1(a)). DI was the only variable for which IGT, lean and obese control subjects differed significantly from

<table>
<thead>
<tr>
<th>Table 1. Comparison of control and impaired glucose tolerance (IGT) subjects at baseline</th>
<th>Mean values and standard errors of the mean</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IGT</td>
</tr>
<tr>
<td>( n ) Total</td>
<td>Mean (SEM)</td>
</tr>
<tr>
<td>Men:women</td>
<td>34:7:27</td>
</tr>
<tr>
<td>Age (years)</td>
<td>55.6(^a) 2.1</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>30.9(^b) 1.0</td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>5.20(^a) 0.15</td>
</tr>
<tr>
<td>Glycated haemoglobin (%)</td>
<td>5.67(^a) 0.12</td>
</tr>
<tr>
<td>NEFA (mEq/l)</td>
<td>0.54 (0.04)</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>5.24 (0.16)</td>
</tr>
<tr>
<td>Triacylglycerol (mmol/l)</td>
<td>1.87 (0.14)</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>1.21 (0.06)</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td>3.18 (0.13)</td>
</tr>
<tr>
<td>( S_1 ) (10(^{-5})[min × pmol/l])</td>
<td>5.17(^a) 0.51</td>
</tr>
<tr>
<td>( S_0 ) (10(^{-2})[min])</td>
<td>1.7 (0.1)</td>
</tr>
<tr>
<td>( \text{AIR}_{\text{glu}} ) (10(^2)×pmol/l×10 min)</td>
<td>6.89(^a) 1.18</td>
</tr>
<tr>
<td>DI (10(^+/))</td>
<td>0.32(^a) 0.06</td>
</tr>
</tbody>
</table>

\( \text{NEFA} \), non-esterified fatty acids; \( S_1 \), Insulin sensitivity index; \( S_0 \), glucose effectiveness; \( \text{AIR}_{\text{glu}} \), pancreatic responsivity (area under the insulin response curve for 10 min after intravenous glucose); DI, glucose disposition index.

\(^{a,b,c}\)Mean values within a row with unlike superscript letters were significantly different (\( P<0.05 \)).

\(^*\)Significance of F value from one-anova ANOVA.
Fig. 1. Plasma glucose and insulin concentrations during the frequently sampled intravenous glucose tolerance test. (a), Values in thirty-four subjects with impaired glucose tolerance (●), seven obese controls (▲) and eight lean controls (▼); (b), values before (■) and after (◇) 4-months treatment with the high-carbohydrate–high-glycaemic index diet; (c), values before (◇) and after (△) 4-months treatment with the low-carbohydrate–high-monounsaturated fat diet; (d), values before (●) and after (□) 4-months treatment with the high-carbohydrate–low-glycaemic index diet. Values are means with their standard errors represented by vertical bars.

Table 2. Comparison of subjects in the three diet groups at baseline*†
(Mean values and standard errors of the mean)

<table>
<thead>
<tr>
<th>Diet</th>
<th>High-GI</th>
<th>Low-GI</th>
<th>MUFA</th>
</tr>
</thead>
<tbody>
<tr>
<td>n: Total</td>
<td>Mean</td>
<td>SEM</td>
<td>Mean</td>
</tr>
<tr>
<td>Men:women</td>
<td>2:9</td>
<td>3:10</td>
<td>2:9</td>
</tr>
<tr>
<td>Age (years)</td>
<td>58-8</td>
<td>4-0</td>
<td>55-2</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>29-3</td>
<td>2-2</td>
<td>29-7</td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>5-35</td>
<td>0-28</td>
<td>5-22</td>
</tr>
<tr>
<td>Glycated haemoglobin (%)</td>
<td>5-95</td>
<td>0-18</td>
<td>5-67</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>126</td>
<td>6</td>
<td>129</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>78</td>
<td>3</td>
<td>80</td>
</tr>
<tr>
<td>Si (10⁻⁹/min × pmol/l)</td>
<td>5-61</td>
<td>0-89</td>
<td>4-47</td>
</tr>
<tr>
<td>So (10⁻¹/min)</td>
<td>1-7</td>
<td>0-2</td>
<td>1-7</td>
</tr>
<tr>
<td>AIRglu (10² × pmol/l × 10 min)</td>
<td>6-02</td>
<td>2-07</td>
<td>5-13</td>
</tr>
<tr>
<td>DI (/10)</td>
<td>0-29</td>
<td>0-12</td>
<td>0-22</td>
</tr>
</tbody>
</table>

High-GI, high-carbohydrate–high-glycaemic index diet; low-GI, high-carbohydrate–low-glycaemic index diet; MUFA, low-carbohydrate–high-monounsaturated fat diet; Si, insulin sensitivity index; So, glucose effectiveness; AIRglu, pancreatic responsivity area under the insulin response curve for 10 min after intravenous glucose; DI, glucose disposition index.

* For details of diets see p. 478.
† None of the differences was statistically significant.
rise on MUFA. Individual changes in body weight did not relate to changes in recorded energy intake \( (r \, 0.09, P=0.59) \).

Diastolic blood pressure tended to increase over the first 8 weeks on all three diets (Fig. 3(b)). Over the last 8 weeks diastolic blood pressure remained stable on MUFA and high-GI but fell significantly on low-GI by 8 mmHg. The change in diastolic blood pressure at 16 weeks on low-GI, −3.6 (SEM 1.1) mmHg, differed significantly from changes on low-GI and MUFA at 8 weeks, high GI at 12 weeks, and MUFA at 16 weeks. Changes in systolic blood pressure followed the same trends, but were not statistically significant.

Fasting glucose tends to rise less on low-GI than high-GI or MUFA, but the difference was not significant (Fig. 3(c)). Compared with the change on high-GI, HbA1c increased significantly on MUFA, and decreased non-significantly on low-GI (Fig. 3(d)). Changes in serum total and LDL-cholesterol or triacylglycerol did not differ significantly among dietary treatments (Fig. 4). However, compared with high-GI, HDL-cholesterol decreased significantly on low-GI, with no significant difference on MUFA (Fig. 4). NEFA tended to decrease from baseline, but the differences among diets were not significant (high-GI, −0.037 (SEM 0.046) mEq/l; low-GI, −0.188 (SEM 0.116) mEq/l; MUFA, −0.144 (SEM 0.068) mEq/l).

The plasma glucose and insulin during the FSIGTT for the three treatment groups are shown on Fig. 1. For each FSIGTT test, a fractional SD (FSD) was derived for the estimate of \( SI \) as a measure of the goodness of fit of the data points to the kinetic model (FSD = SD of estimate expressed as a % of the value for \( SI \)). The median value of FSD for the seventy FSIGTT tests in the IGT subjects was 3.15 %, with 71 % of the values being ≤5 %. In the control subjects, the median FSD was 2.3 %, \( SI \) and \( AIR_{pl} \) tended to improve from baseline on the low-GI diet and to deteriorate on high-GI and MUFA (Figs. 5 and 6), but the differences were not significant. Relative to baseline, mean DI increased by 56 % on low-GI and decreased by 16 % on MUFA, with no change on high-GI. After adjusting for baseline values, the increase in DI on low-GI was significantly different from the changes on both MUFA and high-GI (Fig. 5). Changes in DI were not significantly related to individual changes in body weight, nor to recorded energy, carbohydrate or monounsaturated fat intakes, or glycaemic load. The correlation between change in DI and diet GI during treatment was not quite significant \( (r \, 0.23; P=0.070) \) but became significant when adjusted for carbohydrate intake as % of energy \( (r \, 0.34; P=0.044) \).

### Discussion

A low dietary glycaemic load is associated with a reduced risk of developing type 2 diabetes (Salmerón et al. 1997a,b) and is considered desirable in the dietary management of insulin resistance because it reduces postprandial
plasma insulin (Jeppesen et al. 1997; Reaven, 1997). Reducing postprandial insulin may be beneficial because a vicious cycle may exist in which insulin resistance and high plasma insulin exacerbate each other (Kahn et al. 1993; Del Prato et al. 1994). However, there are two different ways of reducing dietary glycaemic load: reducing carbohydrate intake, or reducing diet GI. Our results show that these two manoeuvres do not have the same effects in subjects with IGT: reducing diet GI improved HbA1c, diastolic blood pressure and glucose DI compared with reducing carbohydrate intake.

DI can be considered an index of the ability of the β-cell to compensate for changes in insulin sensitivity by increasing insulin secretion, with a low value indicating reduced β-cell responsiveness (Chen et al. 1988). Although there is a wide range of SI and AIRglu in the normal population, the product of SI × AIRglu (i.e. DI) tends to be constant (Kahn et al. 1993; Clausen et al. 1996). We found that DI improved significantly by over 50% on low-GI relative to both the MUFA and high-GI. Since defects in both insulin sensitivity and β-cell responsiveness are required for type 2 diabetes to develop (Ferrannini, 1998; Gerich, 1998), a treatment associated with sustained improvement in β-cell responsiveness would be expected to reduce conversion from IGT to diabetes. Indeed, in Pima Indians who converted from IGT to diabetes, DI fell by 48% (Weyer et al. 1999). Thus, improved DI could explain why a low diet GI was associated with reduced risk of developing type 2 diabetes in both the Nurses’ Health (Salmerón et al. 1997b) and Health Professionals Follow-up Studies (Salmerón et al. 1997a).

The low-GI diet was associated with increased β-cell responsiveness in the absence of a change in insulin resistance. Since hyperinsulinaemia may promote the atherosclerotic process (Stout, 1990), it can be asked whether increased β-cell responsiveness may have a deleterious long-term effect on cardiovascular disease risk by increasing plasma insulin. The answer is not known, but we do not believe this to be a strong possibility. Increased β-cell responsiveness means that more insulin is secreted for a given change in plasma glucose concentration; it does not necessarily imply an increase in plasma insulin. Indeed, Swinburn et al. (1991) showed that a high-carbohydrate diet improved β-cell responsiveness with no change in insulin sensitivity and that this was associated with a reduction in mean plasma insulin, presumably due to a simultaneously reduced plasma glucose. The results of the UK Prospective Diabetes Study provide evidence that raising plasma insulin does not promote cardiovascular disease, at least in subjects with diabetes. Treatment of type 2 diabetes with insulin or sulfonylurea had similar effects on glycaemic control, but increased plasma insulin significantly compared with the use of metformin. Despite an increase in plasma insulin, the reduction in the risk of developing cardiovascular complications in subjects treated with insulin or sulfonylurea was virtually identical to that in subjects treated with metformin (UK Prospective Diabetes Study Group, 1998).

The high-GI diet contained typical North American foods and is similar to diets used in studies that failed to show any effect of high carbohydrate intake on insulin sensitivity (Borkman et al. 1991; Swinburn et al. 1991; Garg et al. 1992; Hughes et al. 1995). The present results are consistent with this in that high-GI had no effect on insulin sensitivity, pancreatic responsiveness or DI compared with MUFA.

One of the main arguments against a high-carbohydrate diet for insulin-resistant subjects is that it enhances cardiovascular disease risk because of increased serum triacylglycerol and reduced HDL (Garg et al. 1994; Jeppesen et al. 1997). Studies showing these effects are typically 3–6 weeks long and employ metabolically controlled diets with carbohydrate intake increased from 40 to 60% of energy. Several features of our study design could explain why we saw no effect on triacylglycerol and a trend toward increased HDL on high-GI relative to MUFA. The 16-week study period may have missed transient changes in lipids (Parks & Hellerstein, 2000). Schaefer et al. (1995) have suggested that high-carbohydrate diets may not adversely affect blood lipids in ad-libitum situations because the small amount of weight lost may offset the deleterious effects on blood lipids seen when the diets are given on...
an iso-energetic basis. This is consistent with our results in which there was about 0.75 kg weight loss on high-GI relative to MUFA. Furthermore, the 5–7% increase in carbohydrate intake may have been too small to have an effect on triacylglycerol and HDL (Parks & Hellerstein, 2000).

The small, but statistically significant, differences in body weight change between the three dietary treatment groups may have confounded some of the effects observed, but we do not believe they can account for the changes in DI. Despite the significant difference in weight change between the high-GI and MUFA diets, there was no difference in S_t, AIR_{glu} or DI. In addition, after adjusting for baseline values, DI increased significantly on low-GI compared with high-GI, despite statistically significantly less weight loss on low-GI.

Strictly speaking, the present study compared different types of dietary advice. One strength of this approach is that the results obtained are directly applicable to clinical practice since they were attained with diets self-selected by the subjects over a 4-month period. The weaknesses include the facts that the dietary changes were relatively small and we cannot be sure what the subjects actually ate. These weaknesses would have the effect of reducing the magnitude of expected differences in outcomes between dietary treatments, and reducing the power to detect them. Despite this, significant differences in outcome were obtained.

It is well-known that self-reported energy intake is inaccurate, especially among obese subjects who underestimate their true intakes (Heymsfield et al. 1995). However, there is evidence that reported percentage nutrient intakes are fairly reliable (Lissner & Lindroos, 1994). The significant diet \times time interaction for recorded energy intake probably represents reporting error rather than a true difference. If 1570 kJ/d more energy really was consumed on MUFA than low-GI, >5 kg weight would have been gained; however, the observed weight difference was only 0.4 kg. Daily walking for 1 h would be required to expend 1570 kJ/d with no change in weight, an amount of activity that would probably improve insulin sensitivity (Despres & Lamarche, 1994), and is not consistent with the effects we observed on MUFA. Lack of correlation between changes in recorded energy intake and changes in weight, and lack of difference in blood lipids also argue against any significant difference in energy intake in the three diet groups.

Slowing carbohydrate absorption by pharmacological inhibition of carbohydrate digestive enzymes reduces post-prandial insulin and improves insulin sensitivity in subjects with IGT (Chiaison et al. 1996). Also, a low-GI diet has been shown to improve insulin sensitivity measured in vitro in adipocytes and in vivo using a short insulin tolerance test in subjects at risk of cardiovascular disease (Frost et al. 1998). We were unable to show a significant effect of a low-GI diet on insulin sensitivity. Differences

![Fig. 3. Changes in body weight (a); diastolic blood pressure (DBP) (b); fasting plasma glucose (c); and glycated haemoglobin (HbA1c) (d) during the 4-month treatment with the high-carbohydrate–high-glycaemic index (●), high-carbohydrate–low-glycaemic index, low-carbohydrate–high monounsaturated fat (▲) diets. Mean represents the mean of the changes at 1, 2, 3 and 4 months. Values are means with their standard errors represented by vertical bars. *Mean values with unlike superscript letters were significantly different (P<0.05).](https://doi.org/10.1079/BJN2002568)
in the methods of measuring insulin sensitivity, differences in the populations studied, and lack of statistical power may account for the discrepant results. The power of the present study to detect the observed difference in insulin sensitivity was only about 50%. It was lower than expected not because the effect-size was small but because the variation was high. Based on repeated-measures ANOVA, the within-subject variation in $S_I$ was estimated to be 27% of the mean, about twice the value of 14.4% expected from the literature (Ferrari et al. 1991). The values for FSD were acceptably low showing that experimental errors in the estimation of $S_I$ cannot account for the high variation. This suggests that the within-subject variation of the FSIGTT is greater in IGT subjects than normal. In addition, the IGT subjects we studied were quite heterogeneous; in about 67% of them, low insulin sensitivity was the predominant defect, while in about 33% low pancreatic responsiveness was more important.

Recently, changes in insulin secretion and sensitivity in Pima Indians whose glucose tolerance deteriorated from normal to IGT to diabetes over a 5 year period were compared with those in individuals who remained normal (Weyer et al. 1999). Progression from IGT to diabetes was accompanied by a 19% reduction in insulin sensitivity when measured at high plasma insulin (>13 000 pmol/l). However, when measured at a physiological plasma insulin concentration (840 pmol/l) there was no significant change in insulin sensitivity associated with progression from IGT to diabetes (Weyer et al. 1999). Our inability to detect differences in insulin sensitivity may be related to the relatively low mean peak insulin achieved during the FSIGTT test (1000 pmol/l at 22 min declining to <800 pmol/l at 23 min). Furthermore, improving insulin sensitivity may be less important than maintaining insulin secretion for subjects with IGT, since the main factor associated with conversion from IGT to diabetes was a 51% decrease in insulin secretion (Weyer et al. 1999).

We conclude that the long-term effects of altering source of dietary carbohydrate differ from those of altering amount of carbohydrate. High-carbohydrate–low-GI dietary advice may have beneficial effects on $\beta$-cell function in subjects with IGT, and may, therefore, be useful for the dietary management of IGT.

Acknowledgements

This study was supported by the Canadian Diabetes Association and the International Olive Oil Council.
References


Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palma-
son C, Cohen RM & Wolner TMS (1996) The effect of acar-
bose on insulin sensitivity in subjects with impaired glucose

Clausen JO, Borch-Johnsen K, Ibsen H, Bergman RN, Hougaard
P, Winther K & Pedersen O (1996) Insulin sensitivity index,
acute insulin response, and glucose effectiveness in a popu-
lation-based sample of 380 young healthy caucasians: analysis
of the impact of gender, body fat, physical fitness and life-style

Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M &
DeFronzo RA (1994) Effect of sustained physiologic hyper-
insulinaemia and hyperglycaemia on insulin secretion and

Despres JP & Lamarche B (1994) Low-intensity endurance ex-
cise training, plasma lipoproteins and the risk of coronary heart

Ferrannini E (1998) Insulin resistance versus insulin deficiency
in non-insulin-dependent diabetes mellitus: problems and pro-

Reproducibility of insulin sensitivity measured by the minimal

Finegood DT, Hramiak IM & Dupre` J (1990) A modified protocol
for estimation of insulin sensitivity with the minimal model of
glucose kinetics in patients with insulin-dependent diabetes.
*Journal of Clinical Endocrinology and Metabolism 70*,
1538–1549.

*Report of a Joint FAO/WHO Expert Consultation: Carbo-
hydrates in Human Nutrition*. FAO Food and Nutrition Paper
no. 66. Rome: FAO.

Insulin sensitivity in women at risk of coronary heart disease and
the effect of a low glycemic index diet. *Metabolism 47*,
1245–1251.

Garg A, Balle JP, Henry RR, Coulston AM, Griver KA, Raatz
SK, Brinkley L, Chen YDI, Grundy SM, Huet BA & Reaven
GM (1994) Effects of varying carbohydrate content of diet in
patients with non-insulin-dependent diabetes mellitus. *Journal of
the American Medical Association 271*, 1421–1428.

of high and low carbohydrate diets on plasma lipoproteins and
insulin sensitivity in patients with mild NIDDM. *Diabetes 41*,
1278–1285.

Gerich JE (1998) The genetic basis of type 2 diabetes mellitus:
impaired insulin secretion versus impaired insulin sensitivity.
*Endocrine Reviews 19*, 491–503.

Gordon DJ & Rifkin BM (1989) High-density lipoprotein – the
clinical implications of recent studies. *New England Journal of
Medicine 321*, 1311–1316.

Heymsfield SB, Darby PC, Muhlheim LS, Gallagher D, Wolper C
& Allison DB (1995) The calorie: myth, measurement, and rea-
1034S–1041S.

Hokanson JE & Austin MA (1996) Plasma triglyceride level is a
risk factor for cardiovascular disease independent of high-density
lipoprotein cholesterol level: a meta-analysis of popu-
lation-based prospective studies. *Journal of Cardiovascular

Hughes VA, Fiatarone MA, Fielding RA, Ferrara CM, Elahi D &
and exercise on insulin action in older subjects with impaired
426–433.

Indar-Brown K, Norenberg C & Madar Z (1992) Glycemic and
insulinemic responses after ingestion of ethnic foods by
NIDDM and healthy subjects. *American Journal of Clinical
Nutrition 55*, 89–95.

Jenkins DJA, Ghafari H, Wolver TMS, Taylor RH, Barker HM,
between the rate of digestion of foods and postprandial glyca-

Jeppesen J, Schaa P, Jones C, Zhou M-Y, Chen Y-DI & Reaven
GM (1997) Effects of low-fat, high-carbohydrate diets on risk
factors for ischemic heart disease in postmenopausal women.

Kahn SE, Priegeon RL, McCulloch DK, Boyko EJ, Bergman RN,
Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP &
Porte D Jr (1993) Quantification of the relationship between
insulin sensitivity and β-cell function in human subjects: evi-

Lissner L & Lindroos A-K (1994) Is dietary underreporting
macronutrient-specific? *European Journal of Clinical

Luscombe ND, Noakes M & Clifton PM (1999) Diets high and
low in glycemic index versus high monounsaturated fat diets:
effects on glucose and lipid metabolism in NIDDM. *European

Pacini G & Bergman RN (1986) MINMOD: A computer program
to calculate insulin sensitivity and pancreatic responsivity from
the frequently sampled intravenous glucose tolerance test. *Com-
puter Methods and Programs in Biomedicine 23*, 113–122.

Parks EJ & Hellerstein MK (2000) Carbohydrate-induced hyper-
triglycercylerolemia: historical perspective and review of bio-
logical mechanisms. *American Journal of Clinical Nutrition
71*, 412–433.

Reaven GM (1995) Pathophysiology of insulin resistance in

Reaven GM (1997) Do high carbohydrate diets prevent the de-
velopment or attenuate the manifestations (or both) of syndrome
X? A viewpoint strongly against. *Current Opinion in Lipidol-
ogy 8*, 23–27.

Salmeron J, Ascherio A, Rimm EB, Colditz GA, Spiegelman D,
Jenkins DJ, Stampfer MJ, Wing AL & Willett WC (1997a)
 Dietary fiber, glycemic load, and risk of NIDDM in men. *Dia-
betes Care 20*, 545–550.

Salmeron J, Manson JE, Stampfer MJ, Colditz GA, Wing AL &
Willett WC (1997b) Dietary fiber, glycemic load and risk of
non-insulin-dependent diabetes mellitus in women. *Journal of
the American Medical Association 277*, 472–477.

Schaefer EJ, Lichtenstein AH, Lamon-Fava S, McNamara JR,
weight and low-density lipoprotein cholesterol changes after
consumption of a low-fat ad libitum diet. *Journal of the Ameri-
can Medical Association 274*, 1450–1455.

Stout RW (1990) Insulin and atheroma: 20-yr perspective. *Dia-
betes Care 13*, 631–654.

Swaminathan BA, Boyle VL, Bergman RN, Howard BV & Bogardus
C (1991) Deterioration in carbohydrate metabolism and lipopro-
tein changes induced by modern, high fat diet in Pima Indians
and Caucasians. *Journal of Clinical Endocrinology and Metabi-
olism 73*, 156–165.

UK Prospective Diabetes Study Group (1998) Intensive blood-
glucose control with sulfonylureas or insulin compared with
conventional treatment and risk of complications in patients

US Department of Agriculture (1990) *Dietary Guidelines for
Americans*, third ed. DHHS publication no. 273–930.


history of insulin secretory dysfunction and insulin resistance in
the pathogenesis of type 2 diabetes mellitus. *Journal of Clinical
Investigation 104*, 787–794.


